Third Covid-19 candidate vaccine developed by Janssen Pharmaceutical Companies will be tested in clinical trials involving patients in the UK

Phase 3 placebo controlled RCT will involve 30,000 patients and assess a two dose regimen of the vaccine 57 days apart, using the same human adenovirus that provided the vector for Janssen ' s Ebola virus vaccine. A trial of a single dose by Janssen is already underway in the US.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news